Malaria vaccine study for adults in Chocó
Part of Infections clinical trials.
This trial tests a new malaria vaccine in healthy adults. It includes a controlled malaria infection to see how well the vaccine works. Participation lasts about a year with follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 50 years old.
- You need to be generally healthy, as confirmed by a medical check-up and blood tests.
- You must be willing to give written consent and follow the study plan, including blood draws and follow-up visits for 12 months after the malaria challenge.
- You should either have no history of malaria (and not have lived in a malaria area) or have lived in a malaria area for at least 5 years and have had malaria before.
- You must test negative for HIV, hepatitis B, and hepatitis C.
- If you are a woman who can have children, you must have a negative pregnancy test and use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new malaria vaccine in healthy Thai adults. Participants will receive the vaccine and then be exposed to malaria in a controlled setting to see if the vaccine protects them. If you qualify, you'll be closely monitored and treated.
This study gives healthy volunteers a controlled infection with a type of malaria (vivax) to see how the infection behaves and how well curative anti-malaria medicine works. It may help researchers better design and test future malaria vaccines and treatments.
This study will expose healthy adults to a small number of mosquito bites carrying the P. vivax malaria parasite to learn how many bites are needed to cause infection. Participants will be closely monitored and treated in the hospital to ensure safety.
This study tests a new long-acting injection to prevent malaria. It checks safety and how the body handles the drug in healthy adults and adolescents in Rwanda.
This study tests a new vaccine designed to prevent malaria caused by the Plasmodium vivax parasite. It aims to see if the vaccine is safe and produces a good immune response in healthy adults aged 18 to 59.
This study tests an experimental malaria vaccine in healthy adults. The vaccine is given along with other medicines and a controlled exposure to mosquito bites to see how well it protects against malaria.
Hear when a new Plasmodium Vivax Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.